American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

The International Journal of Chronic Obstructive Pulmonary Disease, published by DOVE MEDICAL PRESS LTD, serves as a premier platform for researchers and professionals involved in the study and management of COPD. Established in 2006 and transitioning to an Open Access model in 2009, this journal has quickly gained a reputable standing in various impactful categories, achieving Q1 rankings in Health Policy, Medicine (Miscellaneous), and Public Health, among others. With a focus on disseminating high-quality research, the journal is pivotal for addressing global public health challenges associated with chronic obstructive pulmonary disease. The journal's dedication to open access ensures that vital information reaches a broader audience, fostering advancements in research and clinical practice. By maintaining rigorous peer-review standards and a commitment to the advancement of understanding in COPD, the journal attracts significant contributions from scientists and practitioners worldwide, making it an invaluable resource for ongoing education and research development in this critical area.

International Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.

Integrated Blood Pressure Control is a distinguished Open Access journal published by DOVE MEDICAL PRESS LTD in New Zealand, dedicated to advancing the field of cardiology and cardiovascular medicine as well as internal medicine. With its established timeline from 2009 to 2024, this journal has earned a commendable Q2 ranking in both its categories for 2023, reflecting its significant contribution to clinical research and practice. With an ISSN of 1178-7104, it provides a platform for high-quality, peer-reviewed articles that address the complexities of blood pressure management, aiming to improve patient outcomes and foster discussions among healthcare professionals. The journal's open-access model, implemented since 2008, ensures that research findings are readily available to all, promoting greater accessibility and dissemination of knowledge in this critical area of health. Researchers, professionals, and students alike are encouraged to engage with the latest findings and innovative practices published within this journal, which plays an essential role in shaping the future of blood pressure control and related medical fields.

HYPERTENSION RESEARCH, published by SpringerNature, serves as a premier platform in the field of Cardiology and Cardiovascular Medicine, Internal Medicine, and Physiology. Since its inception in 1992, the journal has built a substantial reputation, currently ranked in the second quartile (Q2) across several categories in 2023, reflecting its influence and high-quality contributions to medical research. With a focus on hypertension, the journal aims to disseminate vital research findings, clinical studies, and innovative treatment strategies to a diverse audience of researchers, healthcare professionals, and students, fostering knowledge exchange in the management of hypertensive conditions. Although it is not an Open Access journal, it offers comprehensive access to its extensive archive of valuable resources, ensuring that critical advancements in the understanding of hypertension are both accessible and impactful. HYPERTENSION RESEARCH is not only essential for those directly involved in cardiovascular and internal medicine practices but also for interdisciplinary scholars who are looking to explore the intersections of physiology and other biomedical fields in their work.

Journal fur Hypertonie is a leading academic journal published by KRAUSE & PACHERNEGG GMBH, dedicated to the critical field of hypertension research. Since its inception in 1998, the journal has served as a vital platform for disseminating pioneering studies and advancements in the diagnosis, treatment, and management of hypertension. Although its Scopus coverage was discontinued in 2016, the journal continues to hold significance within the academic community, evidenced by its ranking of #98 out of 124 in Internal Medicine, placing it in the 21st percentile. This reflects its targeted impact and relevance in the evolving landscape of cardiovascular research. With no Open Access options, the journal remains a specialized resource indispensable for researchers, healthcare professionals, and students focused on enhancing their understanding and clinical practices related to hypertension. The journal's address is MOZARTGASSE 10, GABLITZ 3003, AUSTRIA.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, published by SAGE PUBLICATIONS INC, stands as a vital resource in the fields of Endocrinology and Internal Medicine. With an impressive open access model established in 2014, this journal facilitates broad dissemination of high-quality research that explores the complex mechanisms and clinical implications of the renin-angiotensin-aldosterone system (RAAS). Currently, it is recognized within the 2023 Category Quartiles as Q3 in Endocrinology and Q2 in Internal Medicine, reflecting its significant impact on the scientific community. The journal ranks in the 75th percentile for Internal Medicine and the 57th percentile in Endocrinology according to Scopus, indicating its strong contributions to these disciplines. Covering a rich history from its inception in 2000 to the present, the journal aims to bridge the gap between basic research and clinical practice, thereby enhancing the understanding and treatment of conditions influenced by RAAS. The continuous publication of innovative research makes it an essential reference for researchers, healthcare professionals, and students engaged in these dynamic fields.

JOURNAL OF HYPERTENSION, published by Lippincott Williams & Wilkins, stands at the forefront of cardiovascular research, serving as a premier platform for the dissemination of knowledge in hypertension and related cardiovascular conditions. With an impressive impact factor, this esteemed journal is recognized in Q1 quartile across multiple categories, including Cardiology, Internal Medicine, and Physiology as of 2023, firmly establishing its significance within the academic community. The journal has been a reliable source of cutting-edge research since its inception in 1983, with continued publication through 2024. Researchers can expect a rigorous peer-review process and a diverse array of articles that include original research, reviews, and clinical studies aimed at enhancing the understanding and management of hypertension. Although it is not an open-access journal, the JOURNAL OF HYPERTENSION remains invaluable to clinicians, researchers, and students dedicated to advancing the field of cardiovascular health.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.